Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1614VXK

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | JUL 20 | Powerful new interactive analysis and visualization software, STN AnaVist, now available |
| NEWS 4 | AUG 11 | STN AnaVist workshops to be held in North America |
| NEWS 5 | AUG 30 | CA/CAplus -Increased access to 19th century research documents |
| NEWS 6 | AUG 30 | CASREACT - Enhanced with displayable reaction conditions |
| NEWS 7 | SEP 09 | ACD predicted properties enhanced in REGISTRY/ZREGISTRY |
| NEWS 8 | OCT 03 | MATHDI removed from STN |
| NEWS 9 | OCT 04 | CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices |
| NEWS 10 | OCT 06 | STN AnaVist workshops to be held in North America |
| NEWS 11 | OCT 13 | New CAS Information Use Policies Effective October 17, 2005 |

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

| | |
|---|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:05:34 ON 15 OCT 2005

=> fil uspatful, caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'USPATFULL' ENTERED AT 17:05:50 ON 15 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 17:05:50 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

```
=> s bupropion (3a) metabolite
L1          38 FILE USPATFULL
L2          50 FILE CAPLUS

TOTAL FOR ALL FILES
L3          88 BUPROPION (3A) METABOLITE

=> s "propan-1-ol" and l3
L4           2 FILE USPATFULL
L5           0 FILE CAPLUS

TOTAL FOR ALL FILES
L6           2 "PROPAN-1-OL" AND L3

=> d 1-2 ibib

L6   ANSWER 1 OF 2  USPATFULL on STN
ACCESSION NUMBER:        2002:99440  USPATFULL
TITLE:                   Bupropion metabolites and methods
                         of their synthesis and use
INVENTOR(S):             Fang, Kevin Qun, Wellesley, MA, UNITED STATES
                         Senanayake, Chrisantha Hugh, Shrewsbury, MA, UNITED
                         STATES
                         Grover, Paul, Franklin, MA, UNITED STATES
PATENT ASSIGNEE(S):      SEPRACOR INC. (U.S. corporation)

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002052341      A1   20020502
APPLICATION INFO.:       US 2001-987931     A1   20011116  (9)
RELATED APPLN. INFO.:    Division of Ser. No. US 2000-640725, filed on 18 Aug
                         2000, PENDING Continuation-in-part of Ser. No. US
                         2000-510241, filed on 22 Feb 2000, PENDING

                                NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 1999-122277P    19990301 (60)
                         US 1999-148324P    19990811 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000,
                         WASHINGTON, DC, 20006
NUMBER OF CLAIMS:        126
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      1 Drawing Page(s)
LINE COUNT:              2344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6   ANSWER 2 OF 2  USPATFULL on STN
ACCESSION NUMBER:        2002:5997  USPATFULL
TITLE:                   Bupropion metabolites and methods
                         of use
INVENTOR(S):             Fang, Qun Kevin, Wellesley, MA, United States
                         Senanayake, Chrisantha Hugh, Shrewsbury, MA, United
                         States
                         Grover, Paul, Franklin, MA, United States
PATENT ASSIGNEE(S):      Sepracor, Inc., Marlborough, MA, United States (U.S.
                         corporation)

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 6337328         B1   20020108
```

APPLICATION INFO.: US 2000-640725 20000818 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-510241, filed on 22 Feb 2000

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1999-148324P | 19990811 (60) |
| | US 1999-122277P | 19990301 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jarvis, William R. A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 94
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> select
ENTER ANSWER SET OR SMARTSELECT L# OR (L6):l6
ENTER ANSWER NUMBER OR RANGE (1-):2
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E47 ASSIGNED

=> d sel

| | | |
|---|---|---|
| E1 | 2 | 109889-09-0/RN |
| E2 | 2 | 112727-80-7/RN |
| E3 | 2 | 34911-55-2/RN |
| E4 | 2 | 364-62-5/RN |
| E5 | 2 | 83863-69-8/RN |
| E6 | 2 | 89565-68-4/RN |
| E7 | 2 | 90182-92-6/RN |
| E8 | 2 | 99614-02-5/RN |
| E9 | 1 | 102141-11-7/RN |
| E10 | 1 | 102141-12-8/RN |
| E11 | 1 | 106083-71-0/RN |
| E12 | 1 | 124-68-5/RN |
| E13 | 1 | 153365-82-3/RN |
| E14 | 1 | 18162-48-6/RN |
| E15 | 1 | 192374-14-4/RN |
| E16 | 1 | 192374-15-5/RN |
| E17 | 1 | 287477-53-6/RN |
| E18 | 1 | 291275-45-1/RN |
| E19 | 1 | 291275-46-2/RN |
| E20 | 1 | 292055-71-1/RN |
| E21 | 1 | 292055-72-2/RN |
| E22 | 1 | 31677-93-7/RN |
| E23 | 1 | 32634-66-5/RN |
| E24 | 1 | 34841-35-5/RN |
| E25 | 1 | 34911-51-8/RN |
| E26 | 1 | 357399-43-0/RN |
| E27 | 1 | 357399-44-1/RN |
| E28 | 1 | 357628-59-2/RN |
| E29 | 1 | 357628-60-5/RN |
| E30 | 1 | 357628-62-7/RN |
| E31 | 1 | 357628-63-8/RN |
| E32 | 1 | 357628-64-9/RN |
| E33 | 1 | 357637-16-2/RN |
| E34 | 1 | 357637-18-4/RN |
| E35 | 1 | 386210-39-5/RN |
| E36 | 1 | 386210-40-8/RN |
| E37 | 1 | 386210-41-9/RN |
| E38 | 1 | 50-67-9/RN |

```
E39          1      51-41-2/RN
E40          1      51-61-6/RN
E41          1      80478-42-8/RN
E42          1      80478-43-9/RN
E43          1      82801-49-8/RN
E44          1      87-69-4/RN
E45          1      92264-81-8/RN
E46          1      92264-82-9/RN
E47          1      99102-04-2/RN


=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      17.50      17.71

FILE 'REGISTRY' ENTERED AT 17:08:45 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 OCT 2005  HIGHEST RN 865347-39-3
DICTIONARY FILE UPDATES:  14 OCT 2005  HIGHEST RN 865347-39-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s e26
L7           1 357399-43-0/RN

=> d

L7   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   357399-43-0  REGISTRY
ED   Entered STN:  19 Sep 2001
CN   2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine
```

FS 3D CONCORD
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e18
L8 1 291275-45-1/RN

=> d

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **291275-45-1** REGISTRY
ED Entered STN: 27 Sep 2000
CN Silane, [[(1Z)-1-(3-chlorophenyl)-1-propenyl]oxy](1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 Cl O Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e1
L9 1 109889-09-0/RN

=> d

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **109889-09-0** REGISTRY

ED  Entered STN:  15 Aug 1987
CN  1H-Indazole-3-carboxamide, 1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo-
CN  9-Azabicyclo[3.3.1]nonane, 1H-indazole-3-carboxamide deriv.
OTHER NAMES:
CN  BRL 43694
CN  BRL 43964
CN  Granisetron
CN  Kevatril
FS  STEREOSEARCH
DR  121061-98-1
MF  C18 H24 N4 O
CI  COM
SR  World Health Organization (WHO)
LC  STN Files:  ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources:  WHO

Relative stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

587 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
590 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e2
L10  1 112727-80-7/RN

=> d

L10  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN  **112727-80-7**  REGISTRY
ED  Entered STN:  06 Feb 1988
CN  Benzamide, 4-amino-N-(1R,4S,5R)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, rel- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  1-Azabicyclo[3.3.1]nonane, benzamide deriv.
CN  Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-,

endo-(±)-
OTHER NAMES:
CN Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, endo-
CN Renzapride
CN [(±)-endo]-4-Amino-5-chloro-2-methoxy-N-(1-azabicyclo[3.3.1]non-4-yl)benzamide
FS STEREOSEARCH
DR 125636-29-5, 109828-31-1
MF C16 H22 Cl N3 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CIN, IMSDRUGNEWS, IMSRESEARCH, IPA, MRCK*, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Relative stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

96 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
96 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e3
L11 1 34911-55-2/RN

=> d

L11 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **34911-55-2** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (±)-
OTHER NAMES:
CN (±)-Bupropion
CN α-(tert-Butylamino)-m-chloropropiophenone
CN Amfebutamon
CN Amfebutamone
CN Bupropion
CN Bupropion SR
DR 34841-39-9
MF C13 H18 Cl N O

CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

800 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
804 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e4
L12 1 364-62-5/RN

=> d

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **364-62-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN o-Anisamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]- (7CI, 8CI)
OTHER NAMES:
CN 2-Methoxy-4-amino-5-chloro-N,N-dimethylaminoethylbenzamide
CN 2-Methoxy-5-chloroprocainamide
CN 4-Amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide
CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide
CN 4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide
CN 5-Chloro-2-methoxyprocainamide
CN AHR 3070C
CN Clopromate
CN DEL 1267
CN Draclamid
CN Emperal
CN Eucil
CN Gastrese
CN Gastro-tablinen
CN Gastro-Timelets
CN Gastrobid
CN Gastromax
CN Gastrosil
CN Gastrotem
CN Maxeran

CN  MCP-ratiopharm
CN  Meclopran
CN  Metamide
CN  Methochlopramide
CN  Metochlopramide
CN  Metoclol
CN  Metoclopramide
CN  Metocobil
CN  Metramid
CN  Moriperan
CN  N-(2-Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
CN  N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorbenzamide
CN  N-(Diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide
CN  N-[2-(Diethylamino)ethyl]-4-amino-5-chloro-2-methoxybenzamide
CN  Parmid
CN  Plasil
CN  Plasil (pharmaceutical)
CN  Primperan
CN  Regla
CN  Reliveran
FS  3D CONCORD
MF  C14 H22 Cl N3 O2
CI  COM
LC  STN Files:  ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
    BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
    CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU,
    EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS,
    IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT,
    PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT,
    USAN, USPAT2, USPATFULL, VETU
      (*File contains numerically searchable property data)
    Other Sources:  EINECS**, WHO
      (**Enter CHEMLIST File for up-to-date regulatory information)




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2327 REFERENCES IN FILE CA (1907 TO DATE)
  21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2331 REFERENCES IN FILE CAPLUS (1907 TO DATE)
  15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e5
L13  1 83863-69-8/RN

=> d

L13  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN  **83863-69-8**  REGISTRY
ED  Entered STN:  16 Nov 1984
CN  Benzamide, 4-amino-5-chloro-2-methoxy-N-[(3R,4S)-3-methoxy-4-piperidinyl]-
    , rel- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  Benzamide, 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)-, cis-

OTHER NAMES:
CN (±)-Norcisapride
CN Norcisapride
FS STEREOSEARCH
DR 86718-38-9
MF C14 H20 Cl N3 O3
SR European Union (EU)
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, IMSRESEARCH, PHAR, TOXCENTER, USPAT2, USPATFULL
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Relative stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

35 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
35 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e6
L14 1 89565-68-4/RN

=> d

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **89565-68-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-3-carboxylic acid, (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-
OTHER NAMES:
CN ICS 205-930
CN ICS 205930
CN Navoban
CN Tropisetron
FS STEREOSEARCH
DR 121061-97-0
MF C17 H20 N2 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Relative stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

540 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
541 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e7
L15 1 90182-92-6/RN

=> d

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **90182-92-6** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzamide, 4-amino-N-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Zacopride
CN (RS)-Zacopride
CN Racemic zacopride
CN Zacopride
FS 3D CONCORD
DR 131104-11-5
MF C15 H20 Cl N3 O2
CI COM
LC STN Files: ADISINSIGHT, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

187 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
188 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s e8
L16          1 99614-02-5/RN

=> d

L16  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   99614-02-5  REGISTRY
ED   Entered STN:  04 Jan 1986
CN   4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-
     yl)methyl]- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1,2,3,4-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-9H-
     carbazol-4-one
CN   GR 38032
CN   GR 38032X
CN   Ondansetron
CN   Zofran
CN   Zophren
CN   Zudan
FS   3D CONCORD
DR   808754-64-5, 108303-49-7, 116002-70-1
MF   C18 H19 N3 O
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
       CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIUDB,
       IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*,
       NIOSHTIC, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          1226 REFERENCES IN FILE CA (1907 TO DATE)
            18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
          1230 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e9
L17          1 102141-11-7/RN

=> d

L17  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   102141-11-7  REGISTRY
ED   Entered STN:  17 May 1986
```

CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-
, (αS)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenemethanol, 3-chloro-α-[1-[(1,1-dimethylethyl)amino]ethyl]-,
(R*,S*)-(+)-
FS STEREOSEARCH
MF C13 H20 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e10
L18 1 102141-12-8/RN

=> d

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **102141-12-8** REGISTRY
ED Entered STN: 17 May 1986
CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e11

L19 1 106083-71-0/RN

=> d

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **106083-71-0** REGISTRY
ED Entered STN: 10 Jan 1987
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, hydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, hydrochloride, [S-(R*,R*)]-
OTHER NAMES:
CN BW 306U
CN GW 353162A
CN Radafaxine hydrochloride
FS STEREOSEARCH
MF C13 H18 Cl N O2 . Cl H
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSRESEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
CRN (192374-14-4)

Absolute stereochemistry. Rotation (+).




● HCl

14 REFERENCES IN FILE CA (1907 TO DATE)
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e12
L20 1 124-68-5/RN

=> d

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **124-68-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Propanol, 2-amino-2-methyl- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN β-Aminoisobutanol
CN 1,1-Dimethyl-2-hydroxyethylamine
CN 2,2-Dimethylethanolamine
CN 2-Amino-1-hydroxy-2-methylpropane
CN 2-Amino-2,2-dimethylethanol
CN 2-Amino-2-methyl-1-propanol
CN 2-Amino-2-methylpropanol
CN 2-Aminoisobutanol

CN 2-Hydroxy-1,1-dimethylethylamine
CN 2-Hydroxymethyl-2-propylamine
CN 2-Methyl-2-amino-1-propanol
CN 2-Methyl-2-aminopropanol
CN AMP
CN AMP (thinner)
CN AMP 75
CN AMP 90
CN AMP 90 (amine)
CN AMP 95
CN AMP Regular
CN Corrguard 75
CN Hydroxy-tert-butylamine
CN Isobutanol-2-amine
CN KV 5088
CN NSC 441
CN Pamabron
FS 3D CONCORD
DR 189832-99-3
MF C4 H11 N O
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2897 REFERENCES IN FILE CA (1907 TO DATE)
144 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2902 REFERENCES IN FILE CAPLUS (1907 TO DATE)
16 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e13
L21 1 153365-82-3/RN

=> d

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **153365-82-3** REGISTRY
ED Entered STN: 02 Mar 1994
CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s e14
L22           1 18162-48-6/RN

=> d

L22  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   18162-48-6  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Silane, chloro(1,1-dimethylethyl)dimethyl- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Silane, chloro-tert-butyldimethyl- (8CI)
OTHER NAMES:
CN   (1,1-Dimethylethyl)dimethylsilyl chloride
CN   Chloro(1,1-dimethylethyl)dimethylsilane
CN   Chloro-tert-butyldimethylsilane
CN   Chlorodimethyl-tert-butylsilane
CN   Dimethyl(1,1-dimethylethyl)chlorosilane
CN   Dimethyl-tert-butylchlorosilane
CN   Dimethyl-tert-butylsilyl chloride
CN   t-Butyldimethylchlorosilane
CN   TBDMS chloride
CN   TBDMS-Cl
CN   tert-Butylchlorodimethylsilane
CN   tert-Butyldimethylchlorosilane
CN   tert-Butyldimethylsilyl chloride
FS   3D CONCORD
DR   132560-73-7, 187979-91-5
MF   C6 H15 Cl Si
LC   STN Files:   AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS,
       CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,
       GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, PS,
       RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, NDSL**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

4127 REFERENCES IN FILE CA (1907 TO DATE)
37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4137 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e15
L23 1 192374-14-4/RN

=> d

L23 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **192374-14-4** REGISTRY
ED Entered STN: 08 Aug 1997
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S-cis)-
OTHER NAMES:
CN (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
CN GW 353162
CN Radafaxine
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, CASREACT, EMBASE, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e16
L24 1 192374-15-5/RN

=> d

L24 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **192374-15-5** REGISTRY
ED Entered STN: 08 Aug 1997
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3R)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R-cis)-
OTHER NAMES:
CN (-)-(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
FS STEREOSEARCH

MF  C13 H18 Cl N O2
CI  COM
SR  CA
LC  STN Files:  CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.  Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d

L24  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN  **192374-15-5**  REGISTRY
ED  Entered STN:  08 Aug 1997
CN  2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3R)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R-cis)-
OTHER NAMES:
CN  (-)-(2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol
FS  STEREOSEARCH
MF  C13 H18 Cl N O2
CI  COM
SR  CA
LC  STN Files:  CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.  Rotation (-).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e17
L25  1 287477-53-6/RN

=> d

L25 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **287477-53-6** REGISTRY
ED Entered STN: 28 Aug 2000
CN 1-Propanone, 1-(3-chlorophenyl)-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H9 Cl O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e18
L26 1 291275-45-1/RN

=> d

L26 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **291275-45-1** REGISTRY
ED Entered STN: 27 Sep 2000
CN Silane, [[(1Z)-1-(3-chlorophenyl)-1-propenyl]oxy](1,1-dimethylethyl)dimethyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H23 Cl O Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e19

L27 1 291275-46-2/RN

=> d

L27 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **291275-46-2** REGISTRY
ED Entered STN: 27 Sep 2000
CN 1-Propanone, 1-(3-chlorophenyl)-2-hydroxy-, (2R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C9 H9 Cl O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e20
L28 1 292055-71-1/RN

=> d

L28 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **292055-71-1** REGISTRY
ED Entered STN: 02 Oct 2000
CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
, hydrochloride, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
CRN (102141-12-8)

Absolute stereochemistry. Rotation (+).




● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s e21
L29          1 292055-72-2/RN

=> d

L29  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   292055-72-2  REGISTRY
ED   Entered STN:  02 Oct 2000
CN   Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-
     , (αR)- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C13 H20 Cl N O
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               3 REFERENCES IN FILE CA (1907 TO DATE)
               3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e22
L30          1 31677-93-7/RN

=> d

L30  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   31677-93-7  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
     hydrochloride (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
     hydrochloride, (±)-
CN   Propiophenone, 2-(tert-butylamino)-3'-chloro-, hydrochloride, (±)-
     (8CI)
OTHER NAMES:
CN   α-(tert-Butylamino)-m-chloropropiophenone hydrochloride
CN   Bupropion hydrochloride
CN   DL-α-t-Butylamino-3-chloropropiophenone hydrochloride
CN   m-Chloro-α-tert-butylaminopropiophenone hydrochloride
CN   NSC 315851
CN   Wellbatrin
CN   Wellbutrin
CN   Zyban
CN   Zyban (pharmaceutical)
DR   34841-36-6
MF   C13 H18 Cl N O . Cl H
CI   COM
```

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (34911-55-2)




● HCl

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

169 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
169 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e23
L31 1 32634-66-5/RN

=> d

L31 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **32634-66-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-Di-O,O'-p-toluoyltartaric acid
CN (-)-Di-O-p-toluoyl-L-tartaric acid
CN (-)-Di-p-toluoyltartaric acid
CN (-)-O,O-Di-p-toluoyltartaric acid
CN (2R,3R)-(-)-Di(p-toluoyl)tartaric acid
CN (R,R)-O,O'-Di-p-toluoyltartaric acid
CN Di-4-toluoyl-L-tartaric acid
CN Di-p-Toluoyl-d-tartaric acid
CN Di-p-toluoyl-L-tartaric acid
CN L-Di-O,O'-p-toluyltartaric acid
CN Tartaric acid, di-p-toluate
AR 100168-11-4
FS STEREOSEARCH
DR 131774-02-2, 64101-05-9, 104695-67-2, 76210-55-4, 79780-69-1, 47375-16-6, 47591-89-9
MF C20 H18 O8
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA, MSDS-OHS, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

186 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
186 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e24
L32 1 34841-35-5/RN

=> d

L32 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **34841-35-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Propanone, 1-(3-chlorophenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propiophenone, 3'-chloro- (6CI, 7CI)
OTHER NAMES:
CN 1-(3-Chlorophenyl)-1-propanone
CN 3-Chlorophenyl ethyl ketone
CN m-Chloropropiophenone
FS 3D CONCORD
MF C9 H9 Cl O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, PROMT, PS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

61 REFERENCES IN FILE CA (1907 TO DATE)
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e25
L33 1 34911-51-8/RN

=> d

L33 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **34911-51-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Propanone, 2-bromo-1-(3-chlorophenyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propiophenone, 2-bromo-3'-chloro- (7CI)
OTHER NAMES:
CN α-Bromo-3-chloropropiophenone
CN α-Bromo-m-chloropropiophenone
CN 2-Bromo-3'-chloropropiophenone
FS 3D CONCORD
DR 92821-81-3
MF C9 H8 Br Cl O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, IFICDB, IFIPAT, IFIUDB, PS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

29 REFERENCES IN FILE CA (1907 TO DATE)
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e26
L34 1 357399-43-0/RN

=> d

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357399-43-0** REGISTRY
ED Entered STN: 19 Sep 2001
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine
FS 3D CONCORD
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e27
L35 1 357399-44-1/RN

=> d

L35 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357399-44-1** REGISTRY
ED Entered STN: 19 Sep 2001
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with (2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3S)-, (2R,3R)-2,3-bis[(4-methylbenzoyl)oxy]butanedioate (1:1) (salt) (9CI)
FS STEREOSEARCH
MF C20 H18 O8 . C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

CM 1

CRN 192374-14-4
CMF C13 H18 Cl N O2

Absolute stereochemistry. Rotation (+).



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e28
L36 1 357628-59-2/RN

=> d

L36 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357628-59-2** REGISTRY
ED Entered STN: 20 Sep 2001
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-, (2R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e29
L37 1 357628-60-5/RN

=> d

L37 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357628-60-5** REGISTRY
ED Entered STN: 20 Sep 2001
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
CI COM

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e30
L38 1 357628-62-7/RN

=> d

L38 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357628-62-7** REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (292055-72-2)

Absolute stereochemistry.




● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e31
L39 1 357628-63-8/RN

=> d

L39 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN **357628-63-8** REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 153365-82-3
CMF C13 H20 Cl N O

Absolute stereochemistry. Rotation (-).




CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e32
L40 1 357628-64-9/RN

=> d

L40 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357628-64-9** REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 102141-12-8
CMF C13 H20 Cl N O

Absolute stereochemistry. Rotation (+).




CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.




2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e33
L41 1 357637-16-2/RN

=> d

L41 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357637-16-2** REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (102141-11-7)

Absolute stereochemistry. Rotation (+).




● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e34
L42 1 357637-18-4/RN

=> d

L42 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357637-18-4** REGISTRY
ED Entered STN: 20 Sep 2001
CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H20 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (153365-82-3)

Absolute stereochemistry. Rotation (-).




● HCl

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e35
L43 1 386210-39-5/RN

=> d

L43 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **386210-39-5** REGISTRY
ED Entered STN: 24 Jan 2002
CN Butanedioic acid, 2,3-bis[(4-methylbenzoyl)oxy]-, (2R,3R)-, compd. with (2R,3R)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H18 O8 . C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 192374-15-5
CMF C13 H18 Cl N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 32634-66-5
CMF C20 H18 O8

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e44
L44 1 87-69-4/RN

=> s e36
L45 1 386210-40-8/RN

=> d

L45 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **386210-40-8** REGISTRY
ED Entered STN: 24 Jan 2002
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2R,3S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e37
L46 1 386210-41-9/RN

=> d

L46 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **386210-41-9** REGISTRY
ED Entered STN: 24 Jan 2002
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2S,3R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e38
L47 1 50-67-9/RN

=> d

L47 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **50-67-9** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indol-5-ol, 3-(2-aminoethyl)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indol-5-ol, 3-(2-aminoethyl)- (6CI, 8CI)
OTHER NAMES:
CN 3-(β-Aminoethyl)-5-hydroxyindole
CN 3-(2-Aminoethyl)-1H-indol-5-ol
CN 3-(2-Aminoethyl)indol-5-ol
CN 5-HT
CN 5-HTA
CN 5-Hydroxy-3-(β-aminoethyl)indole
CN 5-Hydroxyltryptamine
CN 5-Hydroxytriptamine
CN 5-Hydroxytryptamine
CN Antemovis
CN DS substance
CN Enteramin

CN Enteramine
CN Serotonin
CN Substance DS
CN Thrombocytin
CN Thrombotonin
CN Tryptamine, 5-hydroxy-
FS 3D CONCORD
DR 33361-47-6
MF C10 H12 N2 O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

51386 REFERENCES IN FILE CA (1907 TO DATE)
303 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
51414 REFERENCES IN FILE CAPLUS (1907 TO DATE)
205 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s e45
L48 1 92264-81-8/RN

=> d

L48 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **92264-81-8** REGISTRY
ED Entered STN: 16 Nov 1984
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
DR 82793-84-8
MF C13 H18 Cl N O2
CI COM
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, MEDLINE, TOXCENTER, USPATFULL



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

22 REFERENCES IN FILE CA (1907 TO DATE)
22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e3 or e9 or e10 or e13 or e20-22 or e30-e34
L49 12 34911-55-2/RN OR 102141-11-7/RN OR 102141-12-8/RN OR 153365-82-3 /RN OR (292055-71-1/RN OR 292055-72-2/RN OR 31677-93-7/RN) OR (357628-62-7/RN OR 357628-63-8/RN OR 357628-64-9/RN OR 357637-16 -2/RN OR 357637-18-4/RN)

=> fil uspatful , caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 92.76 110.47

FILE 'USPATFULL' ENTERED AT 17:30:20 ON 15 OCT 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 17:30:20 ON 15 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l49
L50 293 FILE USPATFULL
L51 938 FILE CAPLUS

TOTAL FOR ALL FILES
L52 1231 L49

=> d l51 925-938 hit, hitstr, ibib

L51 ANSWER 925 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB The ability of antidepressant drugs, electroconvulsive treatment (ECT) or LiCl to modify prolactin [9002-62-4] secretion in the rat was studied. Chlorimipramine [303-49-1], citalopram [59729-33-8], fluoxetine [54910-89-3], imipramine [50-49-7], and zimelidine [56775-88-3] potentiated the low dose 5-hydroxytryptophan (5-HTP)-induced increase in prolactin secretion, suggesting inhibition of 5-HT [50-67-9] uptake by these drugs. Amitriptyline [50-48-6], doxepin [1668-19-5], iprindole [5560-72-5], mianserin [24219-97-4], and trazodone [19794-93-5] inhibited the prolactin-stimulating effects of high doses of 5-HTP and quipazine, suggesting that these drugs have 5-HT receptor blocking properties. Tandamine [42408-80-0] inhibited only 5-HTP-induced increase in prolactin secretion. Chronic administration of imipramine potentiated the effect of low dose 5-HTP significantly more than an acute dose. Amitriptyline produced similar inhibition of the 5-HTP-induced increase in prolactin secretion after both acute and chronic administration. The ability of bupropion [**34911-55-2**] and mazindol [22232-71-9] to inhibit α-methylparatyrosine-induced prolactin secretion, and of nomifensine to inhibit reserpine-induced prolactin secretion, is consistent with other evidence that these agents are indirect dopamine (DA) [51-61-6] agonists. Desipramine [50-47-5], acutely, had no effect on any of the above paradigms, but after chronic administration, potentiated the effect of low dose 5-HTP on prolactin secretion. Nortriptyline [72-69-5] had no effect on prolactin secretion after acute or chronic treatment. ECT for 10 days did not affect the ability of a 5-HT agonist or d-amphetamine to modify prolactin secretion. However, chronic, but not acute, treatment with LiCl markedly enhanced the prolactin response to 5-HT agonists and reserpine while shifting the dose response curve for d-amphetamine and apomorphine to the right. These results are discussed in light of current theories of the role of 5-HT and

DA in depression.
IT 50-47-5 50-48-6 50-49-7 72-69-5 303-49-1 1668-19-5 5560-72-5 7447-41-8, biological studies 19794-93-5 22232-71-9 24219-97-4 **34911-55-2** 42408-80-0 54910-89-3 56775-88-3 59729-33-8
RL: BIOL (Biological study)
(prolactin of blood serum response to, dopamine and hydroxytryptamine in relation to)
IT **34911-55-2**
RL: BIOL (Biological study)
(prolactin of blood serum response to, dopamine and hydroxytryptamine in relation to)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1981:202641 CAPLUS
DOCUMENT NUMBER: 94:202641
TITLE: Effect of antidepressants, lithium and electroconvulsive treatment on rat serum prolactin levels
AUTHOR(S): Meltzer, H. Y.; Simonovic, M.; Sturgeon, R. D.; Fang, V. S.
CORPORATE SOURCE: Pritzker Sch. Med., Univ. Chicago, Chicago, IL, USA
SOURCE: Acta Psychiatrica Scandinavica, Supplementum (1981), 290(Recent Adv. Treat. Depression), 100-21
CODEN: ASSUA6; ISSN: 0065-1591
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 926 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
IT **34911-55-2**
RL: BIOL (Biological study)
(determination by radioimmunoassay and pharmacokinetics of)
IT **34911-55-2**
RL: BIOL (Biological study)
(determination by radioimmunoassay and pharmacokinetics of)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1981:202441 CAPLUS
DOCUMENT NUMBER: 94:202441
TITLE: Studies on the pharmacology and disposition of bupropion in rats and mice, using radioimmunoassay

AUTHOR(S): Butz, Robert
CORPORATE SOURCE: Duke Univ., Durham, NC, USA
SOURCE: (1980) 160 pp. Avail.: Univ. Microfilms Int., Order No. 8105653
From: Diss. Abstr. Int. B 1981, 41(9), 3405
DOCUMENT TYPE: Dissertation
LANGUAGE: English

L51 ANSWER 927 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB The cardiotoxic effects of amitriptyline-HCl (I-HCl) [549-18-8] and imipramine-HCl (II-HCl) [113-52-0] were evaluated by studying their effects on excitable membranes and compared to that of bupropion-HCl (III-HCl) [**31677-93-7**]. In crayfish giant axon, all antidepressants exhibited local anesthetic-like action by reducing the action potential amplitude and maximum rate of upstroke (dv/dt). The tricyclics were the most potent agents in blocking atrial and papillary muscle excitation; however, III was the least toxic of the compds. tested on the cardiac tissue. The quinidine-like action of the tricyclics on cardiac-tissue is probably related to the antiarrhythmic and/or cardiotoxic manifestation in man and animals.
IT 113-52-0 549-18-8 **31677-93-7**
RL: BIOL (Biological study)
(heart toxicity from)
IT **31677-93-7**
RL: BIOL (Biological study)
(heart toxicity from)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1981:76627 CAPLUS
DOCUMENT NUMBER: 94:76627
TITLE: Electrophysiological effects of antidepressants on mammalian hearts and crayfish giant axon
AUTHOR(S): Wang, Ching M.; Parker, Charles H., Jr.; Maxwell, Robert A.
CORPORATE SOURCE: Dep. Pharmacol., Wellcome Res. Lab., Research Triangle Park, NC, USA
SOURCE: Journal of Cardiovascular Pharmacology (1980), 3(1), 101-12
CODEN: JCPCDT; ISSN: 0160-2446
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 928 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB Bupropion-HCl (BW 323U; Wellbutrin)(I) [**31677-93-7**], a novel compound with antidepressant effects in man, reduced immobility in an exptl. helplessness forced swimming antidepressant test in rats as did imipramine and amitriptyline. Higher dosed produced elevated locomotor activity in an automated open field and produced stereotyped sniffing which was

contrasted with apomorphine. When bupropion or desmethylimipramine was given before intracisternal injections of 6-hydroxydopamine, bupropion produced a dose-related selective antagonism of the destruction of dopamine [51-61-6] neurons, while under the same conditions, desmethylimipramine produced a dose-related selective antagonism of the destruction of noradrenergic neurons. Studies in which the dose of bupropion and the dose 6-hydroxydopamine were varied revealed that a dose-related selective antagonism of dopamine depletion by 6-hydroxydopamine occurred when doses .ltorsim. 50 mg/kg, i.p. of bupropion were administered. Some antagonism of norepinephrine depletion also occurred at 100 mg bupropion/kg, i.p. Bupropion also selectively reversed the dopamine depletion produced by α-methyl-m-tyrosine, a finding which is consistent with the view that bupropion is a dopamine uptake inhibitor in vivo. The importance of dopamine systems for the behavioral effects of bupropion were also studied. When the locomotor stimulant effects of bupropion were tested in rats with chronic destruction of dopamine neurons produced by 6-hydroxydopamine, bupropion failed to elevate locomotor activity. Rats treated with procedures using 6-hydroxydopamine to produce relatively selective norepinephrine depletions responded to bupropion with locomotor activity stimulation like controls. Rats with similar depletions of either dopamine or norepinephrine were also tested for the ability of low doses of bupropion to reduce immobility in the exptl. helplessness forced swim antidepressant test. Prior destruction of dopamine neurons prevented activity of bupropion in this test. Results indicate that bupropion is a selective dopamine uptake inhibitor in vivo and that dopaminergic systems play an important role in its central nervous system pharmacol.

IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, dopamine uptake inhibition in relation to)

IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, dopamine uptake inhibition in relation to)

RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1980:597747 CAPLUS
DOCUMENT NUMBER: 93:197747
TITLE: Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo
AUTHOR(S): Cooper, Barrett R.; Hester, Teresa J.; Maxwell, Robert A.
CORPORATE SOURCE: Dep. Pharmacol., Burroughs Wellcome Co., Research Triangle Park, NC, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1980), 215(1), 127-34
CODEN: JPETAB; ISSN: 0022-3565
DOCUMENT TYPE: Journal

LANGUAGE: English

L51 ANSWER 929 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB Tricyclic antidepressants (amitriptyline [50-48-6], chlorimipramine [303-49-1], desmethylimipramine [50-47-5], and nortriptyline [72-69-5], all 10 mg/kg i.p.) and monoamine oxidase inhibitors (nialamide [51-12-7] and tranylcypromine [155-09-9], 40 and 5 mg/kg, resp.) given twice daily for 16 days reduced the number of β-adrenergic receptor binding sites in rat cerebral cortex homogenates, as determined from dihydroalprenolol-3H binding. Iprindole [5560-72-5] and bupropion [**34911-55-2**] (10 and 20-80 mg/kg, resp.) had the same effect. However, mianserin [24219-97-4] (10 mg/kg) and 11 other psychoactive drugs had no effect. Thus, drug-treatment-induced lowering of dihydroalprenolol-3H binding sites in cerebral cortex apparently has use as a preclin. test for antidepressant drugs.
IT 50-47-5 50-48-6 51-12-7 72-69-5 155-09-9 303-49-1 5560-72-5 **34911-55-2**
RL: BIOL (Biological study)
(β-adrenergic receptor binding sites of brain reduction by)
IT **34911-55-2**
RL: BIOL (Biological study)
(β-adrenergic receptor binding sites of brain reduction by)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1980:488704 CAPLUS
DOCUMENT NUMBER: 93:88704
TITLE: The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain
AUTHOR(S): Sellinger-Barnette, Mary M.; Mendels, J.; Frazer, A.
CORPORATE SOURCE: VA Hosp., Univ. Pennsylvania Sch. Med., Philadelphia, PA, USA
SOURCE: Neuropharmacology (1980), 19(5), 447-54
CODEN: NEPHBW; ISSN: 0028-3908
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 930 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB Various doses of bupropion-HCl (I) [**31677-93-7**] (Wellbatrin) (5, 10, and 20 mg/kg) were employed as cues in a 2-lever operant discrimination from saline control injections in rats on an FR10 schedule of food reinforcement. Subjects reached and maintained a high level of discrimination in the 0 vs 20 mg I/kg stimulus condition but not at the lower doses. In generalization testing, the following compds. produced dose-related responding on the I lever: viloxazine, nomifensine, caffeine, d-amphetamine, cocaine, methylphenidate, and benzylpiperazine. Drugs that failed to show dose-related generalization included phenethylamine, thyrotropin-releasing hormone, imipramine, nortriptyline, amitriptyline, desipramine, mianserin, chlordiazepoxide, diazepam, scopolamine, phenobarbital, and morphine. With the important exception of viloxazine, the generalization profile of I seems to reflect its previously reported locomotor stimulant effects in the rat rather than its antidepressant activity and suggests that species differences exist between man and rat

with regard to the pharmacol. activity of this new antidepressant.

IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, as discriminative stimulus for antidepressants)

IT **31677-93-7**
RL: BIOL (Biological study)
(behavior response to, as discriminative stimulus for antidepressants)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

| | |
|---|---|
| ACCESSION NUMBER: | 1980:174443 CAPLUS |
| DOCUMENT NUMBER: | 92:174443 |
| TITLE: | Stimulus properties of antidepressants in the rat |
| AUTHOR(S): | Jones, Catherine N.; Howard, James L.; McBennett, S. Teresa |
| CORPORATE SOURCE: | Dep. Pharmacol., Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA |
| SOURCE: | Psychopharmacology (Berlin, Germany) (1980), 67(2), 111-18<br>CODEN: PSCHDL; ISSN: 0033-3158 |
| DOCUMENT TYPE: | Journal |
| LANGUAGE: | English |

L51 ANSWER 931 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Bupropion-HCl (I) [**31677-93-7**], a non-tricyclic compound with antidepressant effects in man, was evaluated for effects on plasma prolactin (PRL) [9002-62-4] and growth hormone (GH) [9002-72-6] levels in normal human subjects, and for effects on plasma PRL levels in a series of pharmacol. studies in normal rats. Single oral doses of 50, 100 or 200 mg of I given to male and female subjects produced a marked suppression (80% decrease) of PRL. Incomplete PRL recovery was observed at the end of 24 h. One hour after I administration there was a +0.56 correlation of percent decrease in PRL levels with I plasma levels. GH showed only small and erratic changes in plasma levels at 1-4 h post-dose. In the rat, single I doses of 25 mg/kg, i.p., failed to lower basal PRL levels. I, however, decreased PRL in rats in which plasma PRL was elevated by pretreatment with α-methyltyrosine, 5-hydroxytryptophan, or quipazine. However I did not counteract the PRL-elevating effect of haloperidol. Results in man and rat are consistent with the view that I has significant dopamine mimetic properties.

IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(growth hormone and prolactin of blood plasma response to)

IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(growth hormone and prolactin of blood plasma response to)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1980:34480 CAPLUS
DOCUMENT NUMBER: 92:34480
TITLE: Influence of bupropion hydrochloride (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat
AUTHOR(S): Stern, W. C.; Rogers, J.; Fang, V.; Meltzer, H.
CORPORATE SOURCE: Dep. Clin. Res., Burroughs Wellcome Co., Research Triangle Park, NC, USA
SOURCE: Life Sciences (1979), 25(20), 1717-24
CODEN: LIFSAK; ISSN: 0024-3205
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 932 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB In conscious unrestrained rats, bupropion (I) [**34911-55-2**] (5 and 10 mg/kg, s.c.) was similar to dexamphetamine and nomifensine in inducing EEG arousal which was reduced or blocked by pretreatment with pimozide (1.7 mg/kg), whereas desipramine (5 mg/kg)-induced arousal was not reduced. I, in contrast to desipramine and nomifensine, prevented 6-hydroxydopamine (125 μg/10 μL)-induced depletion of brain dopamine (II) [51-61-6] but was ineffective against noradrenaline (III) depletion. Dexamphetamine was effective against both II and III depletion. In rat striatal II-sensitive adenylate cyclase preparation, I (100μM) had no effect on the production of either basal or II-stimulated cyclic AMP. Thus, II is involved in at least some of the central actions of I. I may inhibit II uptake in vivo in the rat.
IT **34911-55-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine of brain response to, antidepressant activity in relation to)
IT **34911-55-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine of brain response to, antidepressant activity in relation to)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1980:329 CAPLUS
DOCUMENT NUMBER: 92:329
TITLE: The involvement of dopamine in the central actions of bupropion, a new antidepressant
AUTHOR(S): Canning, H.; Goff, D.; Leach, M. J.; Miller, A. A.; Tateson, J. E.; Wheatley, P. L.
CORPORATE SOURCE: Pharmacol. Lab., Wellcome Res. Lab., Beckenham, UK
SOURCE: British Journal of Pharmacology (1979), 66(1), 104P-105P
CODEN: BJPCBM; ISSN: 0007-1188
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 933 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
AB Bupropion-HCl (I) [**31677-93-7**] (50 and 100 mg, orally) given to volunteers differed from both amitriptyline (25 mg) and dexamphetamine sulfate (10 mg) in effects on performance tests, autonomic variables, EEG changes, and subjective effects. However, I failed to differ from lactose on any of the measures of performance tested. I was devoid of stimulant and sedative properties. I had no cardiovascular or anticholinergic effects and appeared to be an effective potential antidepressant.
IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1979:483503 CAPLUS
DOCUMENT NUMBER: 91:83503
TITLE: A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects
AUTHOR(S): Peck, A. W.; Bye, C. E.; Clubley, M.; Henson, T.; Riddington, C.
CORPORATE SOURCE: Dep. Clin. Pharmacol., Wellcome Res. Lab., Beckenham/Kent, UK
SOURCE: British Journal of Clinical Pharmacology (1979), 7(5), 469-78
CODEN: BCPHBM; ISSN: 0306-5251
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 934 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

AB Rats were successfully trained to discriminate between the injection of 0 and 20 mg/kg of Wellbatrin (bupropion-HCl)(I) [**31677-93-7**], a new antidepressant. The discrimination was observed for over 10 mos. Poor generalization between the I cue and those of 4 tricyclic antidepressants, chlordiazepoxide-HCl [438-41-5] and other psychotropic drugs was observed However, stimulus generalization to 4 classes of drugs producing increases in locomotor activity was demonstrated. Thus, the stimulus properties of I appear to reflect most strongly the locomotor stimulant effects. These data also do not give much support to the idea that antidepressants manifest a common stimulus property in rats.

IT **31677-93-7**
RL: BIOL (Biological study)
(discriminative stimulus properties of, antidepressants in relation to)

IT **31677-93-7**
RL: BIOL (Biological study)
(discriminative stimulus properties of, antidepressants in relation to)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1979:432788 CAPLUS
DOCUMENT NUMBER: 91:32788
TITLE: Discriminative stimulus properties of antidepressants
AUTHOR(S): Howard, J. L.; Jones, C. N.; McBennett, S. T.
CORPORATE SOURCE: Wellcome Res. Lab., Dep. Pharmacol., Triangle Park, NC, 27709, USA
SOURCE: Stimulus Prop. Drugs: Ten Years Prog., [Proc. Int. Symp. Drugs Discrim. Stimuli], 1st (1978), 157-66. Editor(s): Colpaert, Francis C.; Rosecrans, John A. Elsevier: Amsterdam, Neth.
CODEN: 40GXAJ
DOCUMENT TYPE: Conference
LANGUAGE: English

L51 ANSWER 935 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN

IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

IT **31677-93-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1978:182685 CAPLUS
DOCUMENT NUMBER: 88:182685
TITLE: Bupropion hydrochloride ((±) α-t-butylamino-3-chloropropiophenone HCl): a novel antidepressant agent
AUTHOR(S): Soroko, F. E.; Mehta, N. B.; Maxwell, R. A.; Ferris, R. M.; Schroeder, D. H.
CORPORATE SOURCE: Wellcome Res. Lab., Org. Chem. Med. Biochem. Res., Triangle Park, NC, USA
SOURCE: Journal of Pharmacy and Pharmacology (1977), 29(12), 767-70
CODEN: JPPMAB; ISSN: 0022-3573
DOCUMENT TYPE: Journal
LANGUAGE: English

L51 ANSWER 936 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
IT 455-67-4P **31677-93-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **31677-93-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 1976:164445 CAPLUS
DOCUMENT NUMBER: 84:164445
TITLE: α-(tert-Butylamino)-m-chloropropiophenone
INVENTOR(S): Mehta, Nariman B.; Yeowell, David A.
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
SOURCE: Can., 14 pp. Division of Can. 977,777.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| CA 977778 | A2 | 19751111 | CA 1974-213916 | | 19741115 |
| CA 977777 | A1 | 19751111 | CA 1970-99790 | | 19701203 |
| PRIORITY APPLN. INFO.: | | | CA 1970-99790 | A3 | 19701203 |
| | | | GB 1969-59231 | A | 19691204 |

L51 ANSWER 937 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
IT 455-67-4P 6084-17-9P **31677-93-7P** 34841-38-8P 34841-40-2P
34841-41-3P **34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **31677-93-7P 34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA
INDEX NAME)




ACCESSION NUMBER: 1972:33965 CAPLUS
DOCUMENT NUMBER: 76:33965
TITLE: α-Halopropiophenones
INVENTOR(S): Yeowell, David A.
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: Ger. Offen., 22 pp. Division of Ger. Offen. 2,059,618.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 2064934 | A | 19711021 | DE 1970-2064934 | 19701203 |
| GB 1340032 | A | 19731205 | GB 1969-59231 | 19691204 |

| | | | | | |
|---|---|---|---|---|---|
| US 3819706 | A | 19740625 | US 1970-93852 | | 19701130 |
| NL 7017687 | A | 19710608 | NL 1970-17687 | | 19701203 |
| NL 172148 | B | 19830216 | | | |
| NL 172148 | C | 19830718 | | | |
| FR 2081326 | A5 | 19711203 | FR 1970-43470 | | 19701203 |
| FR 2081326 | B1 | 19740830 | | | |
| ZA 7008179 | A | 19720726 | ZA 1970-8179 | | 19701203 |
| AT 302276 | B | 19721010 | AT 1970-10874 | | 19701203 |
| AT 307389 | B | 19730525 | AT 1971-9775 | | 19701203 |
| IL 35781 | A1 | 19730629 | IL 1970-35781 | | 19701203 |
| JP 48025179 | B4 | 19730726 | JP 1970-106403 | | 19701203 |
| ES 386127 | A1 | 19731216 | ES 1970-386127 | | 19701203 |
| NO 131127 | B | 19741230 | NO 1970-4645 | | 19701203 |
| PL 74637 | P | 19741231 | PL 1970-144790 | | 19701203 |
| SE 377933 | B | 19750804 | SE 1970-16354 | | 19701203 |
| DK 134984 | B | 19770221 | DK 1970-6170 | | 19701203 |
| FI 53813 | B | 19780502 | FI 1970-3257 | | 19701203 |
| RO 57979 | P | 19750315 | RO 1970-65195 | | 19701204 |
| CH 569693 | A | 19751128 | CH 1970-18021 | | 19701204 |
| CH 574907 | A | 19760430 | CH 1973-8193 | | 19701204 |
| CS 172338 | P | 19761229 | CS 1970-8205 | | 19701204 |
| CS 209466 | P | 19811231 | CS 1970-1331 | | 19701204 |
| NO 133663 | B | 19760301 | NO 1971-3278 | | 19710902 |
| CS 209466 | P | 19811231 | CS 1972-1331 | | 19720229 |
| US 3885046 | A | 19750520 | US 1973-390845 | | 19730823 |
| DK 7601930 | A | 19760429 | DK 1976-1930 | | 19760429 |
| PRIORITY APPLN. INFO.: | | | GB 1969-59231 | A | 19691204 |
| | | | US 1970-93852 | A3 | 19701130 |
| | | | DK 1970-6170 | A | 19701203 |
| | | | NO 1970-4645 | A | 19701203 |
| | | | CS 1970-8205 | A3 | 19701204 |

L51 ANSWER 938 OF 938 CAPLUS COPYRIGHT 2005 ACS on STN
IT 455-67-4P 936-59-4P 6084-17-9P **31677-93-7P** 34841-38-8P
34841-40-2P 34911-51-8P **34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **31677-93-7P 34911-55-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-,
hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA
INDEX NAME)




ACCESSION NUMBER: 1972:3551 CAPLUS
DOCUMENT NUMBER: 76:3551
TITLE: m-Chloro(or fluoro)-α-(tert-butylamino)propiophenone hydrochloride
INVENTOR(S): Mehta, Nariman B.; Yeowell, David A.
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
SOURCE: Ger. Offen., 29 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 2059618 | A | 19711007 | DE 1970-2059618 | 19701203 |
| DE 2059618 | B2 | 19800710 | | |
| DE 2059618 | C3 | 19810416 | | |
| GB 1340032 | A | 19731205 | GB 1969-59231 | 19691204 |
| US 3819706 | A | 19740625 | US 1970-93852 | 19701130 |
| NL 7017687 | A | 19710608 | NL 1970-17687 | 19701203 |
| NL 172148 | B | 19830216 | | |
| NL 172148 | C | 19830718 | | |
| FR 2081326 | A5 | 19711203 | FR 1970-43470 | 19701203 |
| FR 2081326 | B1 | 19740830 | | |
| ZA 7008179 | A | 19720726 | ZA 1970-8179 | 19701203 |
| AT 302276 | B | 19721010 | AT 1970-10874 | 19701203 |
| AT 307389 | B | 19730525 | AT 1971-9775 | 19701203 |
| IL 35781 | A1 | 19730629 | IL 1970-35781 | 19701203 |
| JP 48025179 | B4 | 19730726 | JP 1970-106403 | 19701203 |
| ES 386127 | A1 | 19731216 | ES 1970-386127 | 19701203 |
| NO 131127 | B | 19741230 | NO 1970-4645 | 19701203 |
| PL 74637 | P | 19741231 | PL 1970-144790 | 19701203 |
| SE 377933 | B | 19750804 | SE 1970-16354 | 19701203 |
| DK 134984 | B | 19770221 | DK 1970-6170 | 19701203 |
| FI 53813 | B | 19780502 | FI 1970-3257 | 19701203 |
| RO 57979 | P | 19750315 | RO 1970-65195 | 19701204 |
| CH 569693 | A | 19751128 | CH 1970-18021 | 19701204 |
| CH 574907 | A | 19760430 | CH 1973-8193 | 19701204 |
| CS 172338 | P | 19761229 | CS 1970-8205 | 19701204 |
| CS 209466 | P | 19811231 | CS 1970-1331 | 19701204 |
| NO 133663 | B | 19760301 | NO 1971-3278 | 19710902 |
| CS 209466 | P | 19811231 | CS 1972-1331 | 19720229 |
| US 3885046 | A | 19750520 | US 1973-390845 | 19730823 |
| DK 7601930 | A | 19760429 | DK 1976-1930 | 19760429 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| GB 1969-59231 | A | 19691204 |
| US 1970-93852 | A3 | 19701130 |
| DK 1970-6170 | A | 19701203 |
| NO 1970-4645 | A | 19701203 |
| CS 1970-8205 | A3 | 19701204 |

=> s 149 and (treat? or provent/ or prophylac? ) and (affective or alcohol or anxiety or (attention deficit) or bipolar or manic or bulimia or (chronic fatigue) or depression or narcolepsy)

'PROVENT/ ' IS NOT A VALID FIELD CODE
For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).

=> s l49 and (treat? or provent? or prophylac? ) and (affective or alcohol or anxiety or (attention deficit) or bipolar or manic or bulimia or (chronic fatigue) or depression or narcolepsy)
L53 226 FILE USPATFULL
L54 236 FILE CAPLUS

TOTAL FOR ALL FILES
L55 462 L49 AND (TREAT? OR PROVENT? OR PROPHYLAC? ) AND (AFFECTIVE OR ALCOHOL OR ANXIETY OR (ATTENTION DEFICIT) OR BIPOLAR OR MANIC OR BULIMIA OR (CHRONIC FATIGUE) OR DEPRESSION OR NARCOLEPSY)

=> s l55 and ( racemic or (optic? (1w) pure) or metabolite)
L56 100 FILE USPATFULL
L57 19 FILE CAPLUS

TOTAL FOR ALL FILES
L58 119 L55 AND (RACEMIC OR (OPTIC? (1W) PURE) OR METABOLITE)

=> d l57 10-19 hit, hitstr, ibib

L57 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
TI Use of **optically pure** (R)-tofisopam for **treating** and preventing **anxiety** disorders, and composition thereof
AB Methods are disclosed using the R enantiomer of tofisopam. This compound is useful in the **treatment** or prevention of **anxiety** or **anxiety** disorders while substantially reducing adverse effects associated with **racemic** tofisopam.
ST tofisopam enantiomer **anxiety**
IT Antidepressants
Antipsychotics
Anxiolytics
Drug delivery systems
Enantiomers
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Stress, animal
(acute stress disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Mental disorder
(agoraphobia; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Disease, animal
(**anxiety** disorder from general medical condition; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(capsules; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Resolution (separation)
(chromatog.; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(controlled-release; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(infusions, i.v.; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT Drug delivery systems
(liqs.; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Mental disorder
(obsession-compulsion; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(oral; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT **Anxiety**
(panic disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Mental disorder
(phobia; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Mental disorder
(post-traumatic stress disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Therapy
(psychotherapy; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Behavior
(social, social phobia; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drugs
(substance-induced **anxiety** disorder; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(suspensions; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(sustained-release; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(tablets; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Drug delivery systems
(transdermal; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT Antidepressants
(tricyclic; (R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT 22345-47-7P, Tofisopam
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT 82059-50-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FMU (Formation, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); USES (Uses)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)
IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 51-71-8, Phenelzine 72-69-5, Nortriptyline 155-09-9, Tranylcypromine 303-49-1, Clomipramine 438-60-8, Protriptyline 439-14-5, Diazepam 846-49-1, Lorazepam 1668-19-5, Doxepin 3564-66-7, (+)-Trimipramine 10262-69-8, Maprotiline 14028-44-5, Amoxapine 14611-51-9,

(-)-Selegiline 19794-93-5, Trazodone 28981-97-7, Alprazolam **34911-55-2**, Bupropion 41935-47-1D, 1,4-Benzodiazepine, derivs. 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 71320-77-9, Moclobemide 79617-96-2, Sertraline 83366-66-9, Nefazodone 93413-69-5, Venlafaxine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT 82059-51-6P
RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

IT **34911-55-2**, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
((R)-tofisopam for **treating** and preventing **anxiety** disorders, use with other agents, and compns.)

RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2001:614880 CAPLUS
DOCUMENT NUMBER: 135:147455
TITLE: Use of **optically pure** (R)-tofisopam for **treating** and preventing **anxiety** disorders, and composition thereof
INVENTOR(S): Landry, Donald W.; Klein, Donald F.
PATENT ASSIGNEE(S): Janus Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2000024400 | A1 | 20000504 | WO 1999-US25040 | 19991027 |
| W: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| RW: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| CA 2348281 | AA | 20000504 | CA 1999-2348281 | 19991027 |
| BR 9914899 | A | 20010717 | BR 1999-14899 | 19991027 |
| EP 1124556 | A1 | 20010822 | EP 1999-970920 | 19991027 |

| | | | | | |
|---|---|---|---|---|---|
| EP 1124556 | B1 | 20040623 | | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | | |
| GB 2367748 | A1 | 20020417 | GB 2001-11739 | | 19991027 |
| JP 2003522112 | T2 | 20030722 | JP 2000-578009 | | 19991027 |
| NZ 511744 | A | 20040430 | NZ 1999-511744 | | 19991027 |
| AT 269705 | E | 20040715 | AT 1999-970920 | | 19991027 |
| PT 1124556 | T | 20041029 | PT 1999-970920 | | 19991027 |
| ES 2224751 | T3 | 20050301 | ES 1999-970920 | | 19991027 |
| ZA 2001003376 | A | 20030909 | ZA 2001-3376 | | 20010425 |
| HK 1040908 | A1 | 20050422 | HK 2002-100988 | | 20020207 |
| PRIORITY APPLN. INFO.: | | | US 1998-105803P | P | 19981027 |
| | | | WO 1999-US25040 | W | 19991027 |

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AB A population pharmacokinetic and pharmacodynamic anal. evaluated the relationships of dose, plasma concns. of bupropion and **metabolites**, and patient covariates with the safety and efficacy of bupropion sustained release (SR) for smoking cessation. A total of 519 outpatient chronic cigarette smokers were randomized to one of three bupropion SR doses: 100, 150, or 300 mg/day or placebo. The bupropion plasma concentration time data were fit and subject-specific Bayesian ests. of clearance were obtained. Logistic regression analyses evaluated the role of dose, concns., and covariates in predicting efficacy and safety endpoints. For the evaluation of efficacy, patients were classified as quitters or non-quitters on the basis of a 4-wk quit variable (defined as complete abstinence for weeks 4-7 of the study). For the evaluation of safety, patients were classified into two categories for each adverse event evaluated, corresponding to whether the patient ever experienced the adverse event during the course of the study or never experienced the event, regardless of whether the event was **treatment**-emergent. The efficacy of bupropion SR in facilitating smoking cessation was found to be related to dose and a mean **metabolite** concentration, and quitting in general was found to be related to the number of cigarettes smoked per day at baseline. Smoking cessation was 1.42, 1.69, and 2.84 times more likely in patients receiving 100, 150, and 300 mg/day of bupropion SR, resp., as compared to placebo ($p = 0.0001$). As the baseline number of cigarettes smoked per day increased, the likelihood of quitting decreased regardless of the **treatment** condition. Insomnia and dry mouth were pos. associated with mean **metabolite** concns., and dry mouth was inversely related to patient weight **Anxiety** was inversely related to predicted steady-state concentration (Cpss), suggesting a pos. effect on this withdrawal symptom. Bupropion SR exhibits a statistically significant dose/plasma level-response relationship for smoking cessation. Dry mouth and insomnia, related to concns., may be managed with dose reduction, with the realization that smoking cessation may be impaired.

IT Antidepressants
Tobacco smoke
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT Drug delivery systems
(sustained-release; plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT **31677-93-7**, Zyban
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 54-11-5, Nicotine

RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT 92264-82-9 99102-04-2
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

IT **31677-93-7**, Zyban
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(plasma concentration of bupropion sustained release and **metabolites** for smoking cessation in humans)

RN 31677-93-7 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 2001:605974 CAPLUS
DOCUMENT NUMBER: 135:340398
TITLE: Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation
AUTHOR(S): Johnston, J. Andrew; Fiedler-Kelly, Jill; Glover, Elbert D.; Sachs, David P. L.; Grasela, Thaddeus H.; De Veaugh-Geiss, Joseph
CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA
SOURCE: Nicotine & Tobacco Research (2001), 3(2), 131-140
CODEN: NTREF6; ISSN: 1462-2203
PUBLISHER: Carfax Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
TI Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**
AB Bupropion is widely used in the **treatment** of **depression** and as an anti-craving medication for the cessation of tobacco smoking. Because it is a very weak inhibitor of norepinephrine (NE) and dopamine (DA) reuptake, its mechanisms of action remain to be elucidated. Bupropion was administered s.c. via osmotic minipumps over 2 days to determine its effects on the spontaneous firing activity of NE, serotonin (5-HT), and DA neurons in the brain of anesthetized male Sprague-Dawley rats. This **treatment** was used to obtain levels of the parent compound

and its putatively active **metabolites** that would more adequately reflect the clin. condition than utilizing acute injections. When given by minipump for 2 days, bupropion produced a dose-dependent attenuation of the mean spontaneous firing NE neurons (7.5 mg/kg per day: 15%; 15 mg/kg per day: 61%; 30 mg/kg per day: 80%) which was reversed by the α2-adrenoceptor antagonist idazoxan. At the highest regimen, the mean firing rate of 5-HT neurons was 100% higher than in control rats, but unaffected in NE-lesioned rats. In contrast, DA neurons in the ventral tegmental area displayed a normal firing rate during the latter bupropion **treatment**. Sustained bupropion administration decreased the firing rate of NE neurons due to an increased activation of their inhibitory somatodendritic α2-adrenoceptors. This effect of the bupropion **treatment** would be attributable mainly to an enhancement of NE release and not to reuptake inhibition. This contention is based essentially on the observation that NE reuptake blockers leave unaltered the firing rate of 5-HT neurons, whereas bupropion enhanced it via a NE-dependent mechanism. The present study did not put into evidence any DA activity of bupropion at the level of the cell body of mesolimbic/cortical DA neurons at a regimen exerting profound alterations of the firing activity of NE and 5-HT neurons.

IT Nerve
(dopaminergic; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT Nerve
(neuron, norepinephrine; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT Nerve
(serotoninergic; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α2; modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT **34911-55-2**, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

IT **34911-55-2**, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2001:374861 CAPLUS

DOCUMENT NUMBER: 135:147350
TITLE: Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion **treatment**
AUTHOR(S): Dong, Jianming; Blier, Pierre
CORPORATE SOURCE: Department of Psychiatry and Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL, 32610, USA
SOURCE: Psychopharmacology (Berlin, Germany) (2001), 155(1), 52-57
CODEN: PSCHDL; ISSN: 0033-3158
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
TI Methods and compositions for **treating** or preventing sleep disturbances using very low doses of cyclobenzaprine
AB Methods and compns. comprising a very low dose of cyclobenzaprine or **metabolite** thereof are provided for preventing and **treating** sleep disturbances and illnesses manifested with sleep dysfunction, including fibromyalgia syndrome, **chronic fatigue** syndrome, sleep disorders, psychogenic pain disorders or chronic pain syndromes or symptoms thereof. Also provided are methods and compns. for **treating** sleep disturbances, chronic pain or fatigue in humans suffering from fibromyalgia syndrome, **chronic fatigue** syndrome, sleep disorders, psychogenic pain disorders, chronic pain syndromes using a very low dose of cyclobenzaprine.
IT Antidepressants
(atypical; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Drug delivery systems
(capsules; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Fatigue, biological
(**chronic fatigue** syndrome; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Pain
(chronic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Phototherapy
(combination with light-box therapy; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Therapy
(combination with psychotherapy; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Analgesics
Anti-inflammatory agents
**Anxiety**
Autoimmune disease
Fatigue, biological
Stress, animal
(cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Sleep
(disorder; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)
IT Muscle, disease
(fibromyalgia; cyclobenzaprine in low dose for **treating** or

preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(oral; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(parenterals; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(prodrugs; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Pain
(psychogenic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drugs
(sleep disturbance associated with; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(tablets; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Antidepressants
(tricyclic; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT Drug delivery systems
(unit doses; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 72-69-5, Nortriptyline 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-53-7D, Cyclobenzaprine, **metabolites** and prodrugs 438-60-8, Protriptyline 739-71-9, Trimipramine 1668-19-5, Doxepin 6202-23-9, Cyclobenzaprine hydrochloride 10262-69-8, Maprotiline 14028-44-5, Amoxapine 19794-93-5, Trazodone **34911-55-2**, Bupropion 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine 71620-89-8, Reboxetine 79617-96-2, Sertraline 83366-66-9, Nefazodone 93413-69-5, Venlafaxine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-67-9, Serotonin, biological studies 51-41-2, Norepinephrine 51-61-6, Dopamine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT 50-06-6, Phenobarbital, biological studies 57-43-2, Amobarbital 58-25-3, Chlordiazepoxide 64-17-5, Ethanol, biological studies 67-52-7D, Barbituric acid, derivs. 76-73-3, Secobarbital 76-74-4, Pentobarbital 77-02-1, Aprobarbital 115-38-8, Mephobarbital 115-44-6, Talbutal 125-40-6, Butabarbital 439-14-5, Diazepam 604-75-1, Oxazepam 846-49-1, Lorazepam 846-50-4, Temazepam 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 2955-38-6, Prazepam 12794-10-4D, Benzodiazepine, derivs. 17617-23-1, Flurazepam 23092-17-3, Halazepam 23887-31-2, Clorazepate 28911-01-5, Triazolam 28981-97-7, Alprazolam 36735-22-5, Quazepam 59467-70-8, Midazolam
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sleep disturbance associated with; cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

IT **34911-55-2**, Bupropion
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclobenzaprine in low dose for **treating** or preventing sleep disturbances, pain, fatigue, or fibromyalgia)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 2001:137009 CAPLUS
DOCUMENT NUMBER: 134:173051
TITLE: Methods and compositions for **treating** or preventing sleep disturbances using very low doses of cyclobenzaprine
INVENTOR(S): Iglehart, Iredell W., III
PATENT ASSIGNEE(S): Vela Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2001012175 | A1 | 20010222 | WO 2000-US22082 | 20000811 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2380432 | AA | 20010222 | CA 2000-2380432 | 20000811 |
| BR 2000013017 | A | 20020416 | BR 2000-13017 | 20000811 |
| EP 1202722 | A1 | 20020508 | EP 2000-953996 | 20000811 |
| EP 1202722 | B1 | 20050713 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| GB 2368522 | A1 | 20020508 | GB 2002-2908 | 20000811 |
| US 6395788 | B1 | 20020528 | US 2000-637557 | 20000811 |
| JP 2003506484 | T2 | 20030218 | JP 2001-516521 | 20000811 |
| ES 2192156 | A1 | 20030916 | ES 2002-50016 | 20000811 |
| ES 2192156 | B1 | 20050216 | | |
| NZ 516749 | A | 20040326 | NZ 2000-516749 | 20000811 |
| AT 299369 | E | 20050715 | AT 2000-953996 | 20000811 |
| US 2001046988 | A1 | 20011129 | US 2001-893758 | 20010627 |
| US 6541523 | B2 | 20030401 | | |
| ZA 2002000619 | A | 20030423 | ZA 2002-619 | 20020123 |
| ZA 2002000852 | A | 20030430 | ZA 2002-852 | 20020130 |
| US 2004029869 | A1 | 20040212 | US 2003-392366 | 20030317 |
| PRIORITY APPLN. INFO.: | | | US 1999-148881P | P 19990813 |
| | | | US 2000-637557 | A3 20000811 |

WO 2000-US22082 W 20000811
US 2001-893758 A3 20010627

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AB Several studies in mid-life adults have suggested a curvilinear relationship between bupropion plasma concentration and antidepressant response.

Similarly, elevated levels of bupropion's major **metabolites** have been associated with reduced antidepressant response and increased side effects. These studies have been limited by use of ascending dose designs. We conducted a prospective, randomized, double-blind, fixed-dose study of bupropion **treatment** in 15 elderly subjects diagnosed with major **depression**. Concentration of bupropion and hydroxybupropion (HB), erythrobupropion (EB), and threobupropion (TB) were determined by high performance liquid chromatog. We found bupropion plasma concns. less than 30 ng/mL predicted antidepressant response. Poor antidepressant response was associated with elevated levels of EB and TB, but not HB. Total **metabolite** concentration (HB+EB+TB) was also correlated with severity of adverse side effects. Therapeutic drug monitoring may offer advantages when **treating** older individuals with bupropion, with optimal antidepressant response at bupropion plasma concns. less than 30 ng/mL.

IT Mental disorder
(**depression**, major; bupropion plasma concentration and antidepressant response in elderly patients)

IT **31677-93-7**, Wellbutrin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bupropion plasma concentration and antidepressant response in elderly patients)

IT 92264-81-8 92264-82-9 99102-04-2
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(**metabolite** of bupropion; bupropion plasma concentration and antidepressant response in elderly patients)

IT **31677-93-7**, Wellbutrin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(bupropion plasma concentration and antidepressant response in elderly patients)

RN 31677-93-7 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

ACCESSION NUMBER: 2001:120957 CAPLUS
DOCUMENT NUMBER: 135:175084

TITLE: Bupropion plasma concentration and antidepressant response in elderly patients: A prospective, randomized, double-blind study

AUTHOR(S): Adeoye, O. M.; Sweet, R. A.; Pollock, B. G.; Miller, M. D.; Mulsant, B. H.; Kastango, K. B.; Reynolds, C. F.

CORPORATE SOURCE: Geriatric Psychopharmacology Program, Intervention Research Center for Late-Life Mood Disorders, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

SOURCE: International Journal of Geriatric Psychopharmacology (2000), 2(3), 132-136
CODEN: IJGPFT; ISSN: 1364-8233

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

TI Bupropion **metabolites** and methods of their synthesis and therapeutic uses and compositions

AB Methods and compns. are disclosed which utilize **metabolites** of bupropion for **treating** disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not limited to, erectile dysfunction, **affective** disorders, cerebral function disorders, cigarette smoking, and incontinence. The invention further discloses methods of making **optically pure** bupropion **metabolites**.

ST bupropion **metabolite** synthesis **treatment** monoamine reuptake disorder; erectile dysfunction **treatment** bupropion **metabolite**; **affective** disorder **treatment** bupropion **metabolite**; cigarette smoking **treatment** bupropion **metabolite**; incontinence **treatment** bupropion **metabolite**; **optically pure** bupropion **metabolite**

IT 5-HT antagonists
(5-HT3, adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Antiemetics
(adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Mental disorder
(**affective, treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Anticonvulsants
Antidepressants
Antiparkinsonian agents
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Drug delivery systems
(capsules; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Brain, disease
(cerebrum, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Mental disorder
(**depression, treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Sexual behavior
(impotence, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT Bladder
(incontinence, **treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(mucosal; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Sleep
(**narcolepsy, treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(oral; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Behavior
(smoking, cessation of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(solids; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(solns.; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(tablets; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(transdermal patches; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Drug delivery systems
(transdermal; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Nerve
(**treating** disorder ameliorated by inhibition of monoamine reuptake in; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Monoamines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**treating** disorder ameliorated by inhibition of neuronal reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Epilepsy
Parkinson's disease
(**treatment** of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT Biological transport
(uptake, **treating** disorder ameliorated by inhibition of neuronal monoamine reuptake; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT 364-62-5, Metoclopramide 89565-68-4, Tropisetron 90182-92-6, Zacopride 99614-02-5, Ondansetron 109889-09-0, Granisetron 112727-80-7, Renzapride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjunctive administration with; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT **34911-55-2**, Bupropion 119802-68-5 **292055-72-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
IT **153365-82-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT **102141-12-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 358-23-6, Trifluoromethane sulfonic anhydride
RL: NUU (Other use, unclassified); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 124-68-5, 2-Amino-2-methyl-1-propanol 34841-35-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 291275-45-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 287477-53-6P 291275-46-2P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 192374-15-5P **292055-71-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT **34911-55-2DP**, Bupropion, **metabolites**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 291275-47-3 291275-48-4 291275-49-5 291275-50-8 291275-51-9 291275-52-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 51-41-2, Norepinephrine
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibition of reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 50-67-9, Serotonin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(second pharmacol. active compds. of inhibitors of reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 51-61-6, Dopamine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**treating** disorder ameliorated by inhibition of neuronal reuptake of; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT 54-11-5, Nicotine
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**treatment** of addiction to; bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

IT **34911-55-2**, Bupropion **292055-72-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

RN 34911-55-2 CAPLUS

CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




RN 292055-72-2 CAPLUS

CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **153365-82-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

RN 153365-82-3 CAPLUS

CN Benzenemethanol, 3-chloro-α-[(1R)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **102141-12-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)

RN 102141-12-8 CAPLUS

CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT **292055-71-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
RN 292055-71-1 CAPLUS
CN Benzenemethanol, 3-chloro-α-[(1S)-1-[(1,1-dimethylethyl)amino]ethyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

IT **34911-55-2DP**, Bupropion, **metabolites**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bupropion **metabolites** and methods of synthesis and therapeutic uses and compns.)
RN 34911-55-2 CAPLUS
CN 1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




| | |
|---|---|
| ACCESSION NUMBER: | 2000:627938 CAPLUS |
| DOCUMENT NUMBER: | 133:227784 |
| TITLE: | Bupropion **metabolites** and methods of their synthesis and therapeutic uses and compositions |
| INVENTOR(S): | Jerussi, Thomas P.; McCullough, John R.; Senanayake, Chrisantha H.; Fang, Qun K. |
| PATENT ASSIGNEE(S): | Sepracor Inc., USA |
| SOURCE: | PCT Int. Appl., 41 pp.<br>CODEN: PIXXD2 |
| DOCUMENT TYPE: | Patent |
| LANGUAGE: | English |

L34 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN **357399-43-0** REGISTRY
ED Entered STN: 19 Sep 2001
CN 2-Morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-Hydroxy-2-(3-chlorophenyl)-3,5,5-trimethylmorpholine
FS 3D CONCORD
MF C13 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)